ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced independent, investigator-initiated study abstracts on ZYNLONTA ® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 66 th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 7-10, 2024 "Data from the abstract on the Phase 2 study of ZYNLONTA combined with rituximab in patients with high-risk relapsed or refractory follicular lymphoma demonstrated a robust response among the 35 evaluable patients, with an overall response rate at week 12 of 97.1%," said Mohamed Zaki , MD, PhD, Chief Medical Officer of ADC Therapeutics. "All complete metab
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics SA (NYSE: ADCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ADC Therapeutics SA (NYSE: ADCT) had its price target raised by analysts at Stephens from $6.00 to $8.00. They now have an "overweight" rating on the stock.MarketBeat
- ADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR Newswire
- ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferencePR Newswire
ADCT
Earnings
- 11/7/24 - Beat
ADCT
Sec Filings
- 2/14/25 - Form 4
- 2/14/25 - Form 4
- 2/14/25 - Form 4
- ADCT's page on the SEC website